Loading…
Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry
Abstract Introduction We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers. Methods We used the R egistro I nformatizado E nfermedad T rombo E mbólica (RIETE) registry to validate our prev...
Saved in:
Published in: | TH open : companion journal to thrombosis and haemostasis 2020-07, Vol.4 (3), p.e236-e244 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3 |
container_end_page | e244 |
container_issue | 3 |
container_start_page | e236 |
container_title | TH open : companion journal to thrombosis and haemostasis |
container_volume | 4 |
creator | Siniscalchi, Carmine Suriñach, José M. Visonà, Adriana Fernández-Reyes, José L. Gómez-Cuervo, Covadonga Verhamme, Peter Marchena, Pablo J. Farge-Bancel, Dominique Moisés, Jorge Monreal, Manuel |
description | Abstract
Introduction
We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers.
Methods
We used the
R
egistro
I
nformatizado
E
nfermedad
T
rombo
E
mbólica (RIETE) registry to validate our previous findings in a subsequent cohort of patients and to compare the risk of death according to the use of different types of statins.
Results
From January 2018 to December 2019, 19,557 patients with VTE were recruited in RIETE. Of them, 4,065 (21%) were using statins (simvastatin, 1,406; atorvastatin, 1,328; rosuvastatin, 246; and others, 1,085). During anticoagulation (192 vs.182 days, for statin and no statin users respectively), 500 patients developed a VTE recurrence, 519 suffered major bleeding, and 1,632 died (fatal pulmonary embolism [PE], 88 and fatal bleeding, 78). On multivariable analysis, statin users were at a lower risk to die (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.59–0.79) than nonusers. When separately analyzing the drugs, on multivariable analysis, patients using simvastatin (HR = 0.64; 95% CI: 0.52–0.80), atorvastatin (HR 0.72; 95% CI: 0.58–0.89), or other statins (HR = 0.67; 95% CI: 0.52–0.87) were at a lower risk to die than nonusers. For those using rosuvastatin, difference was not statistically significant (HR = 0.77; 95% CI: 0.50–1.19), maybe due to the sample size.
Conclusion
Our data validate previous findings and confirm that VTE patients using statins at baseline are at a lower risk to die than nonusers. No statistically differences were found according to type of statins. |
doi_str_mv | 10.1055/s-0040-1716734 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eb16d341008e4498bc89d3000bbda1a7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eb16d341008e4498bc89d3000bbda1a7</doaj_id><sourcerecordid>2445424136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3</originalsourceid><addsrcrecordid>eNp1ks1u1DAUhSMEolXplrWXbFL8n4QF0mgYYKQipHbo1nLimxmPnHiwnUp5BZ4al4wQXbCwbNnnfFc-OkXxluAbgoV4H0uMOS5JRWTF-IvikgpCy4ZL8fKf80VxHeMRY0waIiltXhcXjDaSk6q-LH59sn0PAcaEdvMJIvI9uk862TEiPRq0cq5c6ykC-uZD0s6mGZkp2HGPVmOyndf7yWW5H1HvA3qA0U8R7Q7BD62HvJyNwwf0kJ1mkd2nycyozwJ0t93sNugO9jamML8pXvXaRbg-71fFj8-b3fprefv9y3a9ui07RiQvKZEYaF9h3EpGWc1BCt2Kuu2wAArS0BoTIUgludDSSAmkE0Q0HYeq6nnHrortwjVeH9Up2EGHWXlt1Z8LH_ZKh_w1BwpaIg3jBOMaOG_yjLoxLEfZtkYTXWXWx4V1mtoBTJdzDNo9gz5_Ge1B7f2jqjKNYZEB786A4H9OEJMabOzAOT1CTlJRzgWnnDCZpTeLtAs-xgD93zEEq6c-qKie-qDOfciGcjGkg4UB1NFPYczJ_k__G0Fltb0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2445424136</pqid></control><display><type>article</type><title>Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry</title><source>Open Access: Thieme Open Access Journals</source><source>PubMed Central</source><creator>Siniscalchi, Carmine ; Suriñach, José M. ; Visonà, Adriana ; Fernández-Reyes, José L. ; Gómez-Cuervo, Covadonga ; Verhamme, Peter ; Marchena, Pablo J. ; Farge-Bancel, Dominique ; Moisés, Jorge ; Monreal, Manuel</creator><creatorcontrib>Siniscalchi, Carmine ; Suriñach, José M. ; Visonà, Adriana ; Fernández-Reyes, José L. ; Gómez-Cuervo, Covadonga ; Verhamme, Peter ; Marchena, Pablo J. ; Farge-Bancel, Dominique ; Moisés, Jorge ; Monreal, Manuel ; and the RIETE Investigators</creatorcontrib><description>Abstract
Introduction
We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers.
Methods
We used the
R
egistro
I
nformatizado
E
nfermedad
T
rombo
E
mbólica (RIETE) registry to validate our previous findings in a subsequent cohort of patients and to compare the risk of death according to the use of different types of statins.
Results
From January 2018 to December 2019, 19,557 patients with VTE were recruited in RIETE. Of them, 4,065 (21%) were using statins (simvastatin, 1,406; atorvastatin, 1,328; rosuvastatin, 246; and others, 1,085). During anticoagulation (192 vs.182 days, for statin and no statin users respectively), 500 patients developed a VTE recurrence, 519 suffered major bleeding, and 1,632 died (fatal pulmonary embolism [PE], 88 and fatal bleeding, 78). On multivariable analysis, statin users were at a lower risk to die (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.59–0.79) than nonusers. When separately analyzing the drugs, on multivariable analysis, patients using simvastatin (HR = 0.64; 95% CI: 0.52–0.80), atorvastatin (HR 0.72; 95% CI: 0.58–0.89), or other statins (HR = 0.67; 95% CI: 0.52–0.87) were at a lower risk to die than nonusers. For those using rosuvastatin, difference was not statistically significant (HR = 0.77; 95% CI: 0.50–1.19), maybe due to the sample size.
Conclusion
Our data validate previous findings and confirm that VTE patients using statins at baseline are at a lower risk to die than nonusers. No statistically differences were found according to type of statins.</description><identifier>ISSN: 2512-9465</identifier><identifier>ISSN: 2567-3459</identifier><identifier>EISSN: 2512-9465</identifier><identifier>DOI: 10.1055/s-0040-1716734</identifier><identifier>PMID: 32964178</identifier><language>eng</language><publisher>Stuttgart · New York: Georg Thieme Verlag KG</publisher><subject>atorvastatin ; death ; Original ; Original Article ; rosuvastatin ; simvastatin ; venous thromboembolism</subject><ispartof>TH open : companion journal to thrombosis and haemostasis, 2020-07, Vol.4 (3), p.e236-e244</ispartof><rights>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.</rights><rights>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( ). 2020 Georg Thieme Verlag KG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3</citedby><cites>FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3</cites><orcidid>0000-0001-9504-7511 ; 0000-0003-2294-2229 ; 0000-0002-0613-1074</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498305/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498305/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,20891,27924,27925,53791,53793,54587,54615</link.rule.ids></links><search><creatorcontrib>Siniscalchi, Carmine</creatorcontrib><creatorcontrib>Suriñach, José M.</creatorcontrib><creatorcontrib>Visonà, Adriana</creatorcontrib><creatorcontrib>Fernández-Reyes, José L.</creatorcontrib><creatorcontrib>Gómez-Cuervo, Covadonga</creatorcontrib><creatorcontrib>Verhamme, Peter</creatorcontrib><creatorcontrib>Marchena, Pablo J.</creatorcontrib><creatorcontrib>Farge-Bancel, Dominique</creatorcontrib><creatorcontrib>Moisés, Jorge</creatorcontrib><creatorcontrib>Monreal, Manuel</creatorcontrib><creatorcontrib>and the RIETE Investigators</creatorcontrib><title>Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry</title><title>TH open : companion journal to thrombosis and haemostasis</title><addtitle>TH Open</addtitle><description>Abstract
Introduction
We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers.
Methods
We used the
R
egistro
I
nformatizado
E
nfermedad
T
rombo
E
mbólica (RIETE) registry to validate our previous findings in a subsequent cohort of patients and to compare the risk of death according to the use of different types of statins.
Results
From January 2018 to December 2019, 19,557 patients with VTE were recruited in RIETE. Of them, 4,065 (21%) were using statins (simvastatin, 1,406; atorvastatin, 1,328; rosuvastatin, 246; and others, 1,085). During anticoagulation (192 vs.182 days, for statin and no statin users respectively), 500 patients developed a VTE recurrence, 519 suffered major bleeding, and 1,632 died (fatal pulmonary embolism [PE], 88 and fatal bleeding, 78). On multivariable analysis, statin users were at a lower risk to die (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.59–0.79) than nonusers. When separately analyzing the drugs, on multivariable analysis, patients using simvastatin (HR = 0.64; 95% CI: 0.52–0.80), atorvastatin (HR 0.72; 95% CI: 0.58–0.89), or other statins (HR = 0.67; 95% CI: 0.52–0.87) were at a lower risk to die than nonusers. For those using rosuvastatin, difference was not statistically significant (HR = 0.77; 95% CI: 0.50–1.19), maybe due to the sample size.
Conclusion
Our data validate previous findings and confirm that VTE patients using statins at baseline are at a lower risk to die than nonusers. No statistically differences were found according to type of statins.</description><subject>atorvastatin</subject><subject>death</subject><subject>Original</subject><subject>Original Article</subject><subject>rosuvastatin</subject><subject>simvastatin</subject><subject>venous thromboembolism</subject><issn>2512-9465</issn><issn>2567-3459</issn><issn>2512-9465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0U6</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks1u1DAUhSMEolXplrWXbFL8n4QF0mgYYKQipHbo1nLimxmPnHiwnUp5BZ4al4wQXbCwbNnnfFc-OkXxluAbgoV4H0uMOS5JRWTF-IvikgpCy4ZL8fKf80VxHeMRY0waIiltXhcXjDaSk6q-LH59sn0PAcaEdvMJIvI9uk862TEiPRq0cq5c6ykC-uZD0s6mGZkp2HGPVmOyndf7yWW5H1HvA3qA0U8R7Q7BD62HvJyNwwf0kJ1mkd2nycyozwJ0t93sNugO9jamML8pXvXaRbg-71fFj8-b3fprefv9y3a9ui07RiQvKZEYaF9h3EpGWc1BCt2Kuu2wAArS0BoTIUgludDSSAmkE0Q0HYeq6nnHrortwjVeH9Up2EGHWXlt1Z8LH_ZKh_w1BwpaIg3jBOMaOG_yjLoxLEfZtkYTXWXWx4V1mtoBTJdzDNo9gz5_Ge1B7f2jqjKNYZEB786A4H9OEJMabOzAOT1CTlJRzgWnnDCZpTeLtAs-xgD93zEEq6c-qKie-qDOfciGcjGkg4UB1NFPYczJ_k__G0Fltb0</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Siniscalchi, Carmine</creator><creator>Suriñach, José M.</creator><creator>Visonà, Adriana</creator><creator>Fernández-Reyes, José L.</creator><creator>Gómez-Cuervo, Covadonga</creator><creator>Verhamme, Peter</creator><creator>Marchena, Pablo J.</creator><creator>Farge-Bancel, Dominique</creator><creator>Moisés, Jorge</creator><creator>Monreal, Manuel</creator><general>Georg Thieme Verlag KG</general><scope>0U6</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9504-7511</orcidid><orcidid>https://orcid.org/0000-0003-2294-2229</orcidid><orcidid>https://orcid.org/0000-0002-0613-1074</orcidid></search><sort><creationdate>202007</creationdate><title>Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry</title><author>Siniscalchi, Carmine ; Suriñach, José M. ; Visonà, Adriana ; Fernández-Reyes, José L. ; Gómez-Cuervo, Covadonga ; Verhamme, Peter ; Marchena, Pablo J. ; Farge-Bancel, Dominique ; Moisés, Jorge ; Monreal, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>atorvastatin</topic><topic>death</topic><topic>Original</topic><topic>Original Article</topic><topic>rosuvastatin</topic><topic>simvastatin</topic><topic>venous thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siniscalchi, Carmine</creatorcontrib><creatorcontrib>Suriñach, José M.</creatorcontrib><creatorcontrib>Visonà, Adriana</creatorcontrib><creatorcontrib>Fernández-Reyes, José L.</creatorcontrib><creatorcontrib>Gómez-Cuervo, Covadonga</creatorcontrib><creatorcontrib>Verhamme, Peter</creatorcontrib><creatorcontrib>Marchena, Pablo J.</creatorcontrib><creatorcontrib>Farge-Bancel, Dominique</creatorcontrib><creatorcontrib>Moisés, Jorge</creatorcontrib><creatorcontrib>Monreal, Manuel</creatorcontrib><creatorcontrib>and the RIETE Investigators</creatorcontrib><collection>Open Access: Thieme Open Access Journals</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>TH open : companion journal to thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siniscalchi, Carmine</au><au>Suriñach, José M.</au><au>Visonà, Adriana</au><au>Fernández-Reyes, José L.</au><au>Gómez-Cuervo, Covadonga</au><au>Verhamme, Peter</au><au>Marchena, Pablo J.</au><au>Farge-Bancel, Dominique</au><au>Moisés, Jorge</au><au>Monreal, Manuel</au><aucorp>and the RIETE Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry</atitle><jtitle>TH open : companion journal to thrombosis and haemostasis</jtitle><addtitle>TH Open</addtitle><date>2020-07</date><risdate>2020</risdate><volume>4</volume><issue>3</issue><spage>e236</spage><epage>e244</epage><pages>e236-e244</pages><issn>2512-9465</issn><issn>2567-3459</issn><eissn>2512-9465</eissn><abstract>Abstract
Introduction
We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers.
Methods
We used the
R
egistro
I
nformatizado
E
nfermedad
T
rombo
E
mbólica (RIETE) registry to validate our previous findings in a subsequent cohort of patients and to compare the risk of death according to the use of different types of statins.
Results
From January 2018 to December 2019, 19,557 patients with VTE were recruited in RIETE. Of them, 4,065 (21%) were using statins (simvastatin, 1,406; atorvastatin, 1,328; rosuvastatin, 246; and others, 1,085). During anticoagulation (192 vs.182 days, for statin and no statin users respectively), 500 patients developed a VTE recurrence, 519 suffered major bleeding, and 1,632 died (fatal pulmonary embolism [PE], 88 and fatal bleeding, 78). On multivariable analysis, statin users were at a lower risk to die (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.59–0.79) than nonusers. When separately analyzing the drugs, on multivariable analysis, patients using simvastatin (HR = 0.64; 95% CI: 0.52–0.80), atorvastatin (HR 0.72; 95% CI: 0.58–0.89), or other statins (HR = 0.67; 95% CI: 0.52–0.87) were at a lower risk to die than nonusers. For those using rosuvastatin, difference was not statistically significant (HR = 0.77; 95% CI: 0.50–1.19), maybe due to the sample size.
Conclusion
Our data validate previous findings and confirm that VTE patients using statins at baseline are at a lower risk to die than nonusers. No statistically differences were found according to type of statins.</abstract><cop>Stuttgart · New York</cop><pub>Georg Thieme Verlag KG</pub><pmid>32964178</pmid><doi>10.1055/s-0040-1716734</doi><orcidid>https://orcid.org/0000-0001-9504-7511</orcidid><orcidid>https://orcid.org/0000-0003-2294-2229</orcidid><orcidid>https://orcid.org/0000-0002-0613-1074</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2512-9465 |
ispartof | TH open : companion journal to thrombosis and haemostasis, 2020-07, Vol.4 (3), p.e236-e244 |
issn | 2512-9465 2567-3459 2512-9465 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_eb16d341008e4498bc89d3000bbda1a7 |
source | Open Access: Thieme Open Access Journals; PubMed Central |
subjects | atorvastatin death Original Original Article rosuvastatin simvastatin venous thromboembolism |
title | Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A51%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20Types%20of%20Statins%20and%20All-Cause%20Mortality%20during%20Anticoagulation%20for%20Venous%20Thromboembolism:%20Validation%20Study%20from%20RIETE%20Registry&rft.jtitle=TH%20open%20:%20companion%20journal%20to%20thrombosis%20and%20haemostasis&rft.au=Siniscalchi,%20Carmine&rft.aucorp=and%20the%20RIETE%20Investigators&rft.date=2020-07&rft.volume=4&rft.issue=3&rft.spage=e236&rft.epage=e244&rft.pages=e236-e244&rft.issn=2512-9465&rft.eissn=2512-9465&rft_id=info:doi/10.1055/s-0040-1716734&rft_dat=%3Cproquest_doaj_%3E2445424136%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3164-2160e2f700b632384e65ab58bc05e2e6d28015517645a6d66e1c5159c4e77f4c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2445424136&rft_id=info:pmid/32964178&rfr_iscdi=true |